<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25884448</article-id><article-id pub-id-type="pmc">4377036</article-id><article-id pub-id-type="publisher-id">1199</article-id><article-id pub-id-type="doi">10.1186/s12885-015-1199-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Neo-adjuvant <italic>ch</italic>emotherapy followed by surgery <italic>versus</italic> surgery <italic>a</italic>lone in high-<italic>ris</italic>k patients with resectable colorectal liver <italic>m</italic>et<italic>a</italic>stases: the CHARISMA randomized multicenter clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ayez</surname><given-names>Ninos</given-names></name><address><email>n.ayez@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>van der Stok</surname><given-names>Eric P</given-names></name><address><email>e.vanderstok@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>de Wilt</surname><given-names>Hans</given-names></name><address><email>hans.dewilt@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Radema</surname><given-names>Sandra A</given-names></name><address><email>sandra.radema@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>van Hillegersberg</surname><given-names>Richard</given-names></name><address><email>r.vanhillegersberg@umcutrecht.nl</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Roumen</surname><given-names>Rudi M</given-names></name><address><email>r.roumen@mmc.nl</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Vreugdenhil</surname><given-names>Gerard</given-names></name><address><email>g.vreugdenhil@mmc.nl</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Tanis</surname><given-names>Pieter J</given-names></name><address><email>p.j.tanis@amc.nl</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Punt</surname><given-names>Cornelis J</given-names></name><address><email>c.punt@amc.uva.nl</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Dejong</surname><given-names>Cornelis H</given-names></name><address><email>chc.dejong@mumc.nl</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Jansen</surname><given-names>Rob L</given-names></name><address><email>rob.jansen@mumc.nl</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Verheul</surname><given-names>Henk M</given-names></name><address><email>h.verheul@vumc.nl</email></address><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>de Jong</surname><given-names>Koert P</given-names></name><address><email>k.p.de.jong@umcg.nl</email></address><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Hospers</surname><given-names>Geke A</given-names></name><address><email>g.a.p.hospers@umcg.nl</email></address><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Klaase</surname><given-names>Joost M</given-names></name><address><email>j.klaase@mst.nl</email></address><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Legdeur</surname><given-names>Marie-Cecile</given-names></name><address><email>m.legdeur@mst.nl</email></address><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>van Meerten</surname><given-names>Esther</given-names></name><address><email>e.vanmeerten@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Eskens</surname><given-names>Ferry A</given-names></name><address><email>f.eskens@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>van der Meer</surname><given-names>Nelly</given-names></name><address><email>n.vandermeer@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>van der Holt</surname><given-names>Bruno</given-names></name><address><email>b.vanderholt@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Verhoef</surname><given-names>Cornelis</given-names></name><address><email>c.verhoef@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gr&#x000fc;nhagen</surname><given-names>Dirk J</given-names></name><address><email>d.grunhagen@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Surgical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Surgical Oncology, Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands </aff><aff id="Aff3"><label>3</label>Department of Medical Oncology, Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands </aff><aff id="Aff4"><label>4</label>Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands </aff><aff id="Aff5"><label>5</label>Department of Surgery, M&#x000e1;xima Medical Center, Veldhoven, The Netherlands </aff><aff id="Aff6"><label>6</label>Department of Medical Oncology, M&#x000e1;xima Medical Center, Veldhoven, The Netherlands </aff><aff id="Aff7"><label>7</label>Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands </aff><aff id="Aff8"><label>8</label>Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands </aff><aff id="Aff9"><label>9</label>Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands </aff><aff id="Aff10"><label>10</label>Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands </aff><aff id="Aff11"><label>11</label>Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands </aff><aff id="Aff12"><label>12</label>Division of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands </aff><aff id="Aff13"><label>13</label>Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands </aff><aff id="Aff14"><label>14</label>Department of Surgery, Medisch Spectrum Twente, Enschede, The Netherlands </aff><aff id="Aff15"><label>15</label>Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands </aff><aff id="Aff16"><label>16</label>Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands </aff><aff id="Aff17"><label>17</label>Clinical Trial Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>15</volume><elocation-id>180</elocation-id><history><date date-type="received"><day>28</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Ayez et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Efforts to improve the outcome of liver surgery by combining curative resection with chemotherapy have failed to demonstrate definite overall survival benefit. This may partly be due to the fact that these studies often involve strict inclusion criteria. Consequently, patients with a high risk profile as characterized by Fong&#x02019;s Clinical Risk Score (CRS) are often underrepresented in these studies. Conceptually, this group of patients might benefit the most from chemotherapy. The present study evaluates the impact of neo-adjuvant chemotherapy in high-risk patients with primary resectable colorectal liver metastases, without extrahepatic disease. Our hypothesis is that adding neo-adjuvant chemotherapy to surgery will provide an improvement in overall survival (OS) in patients with a high-risk profile.</p></sec><sec><title>Methods/Design</title><p>CHARISMA is a multicenter, randomized, phase III clinical trial. Patients will be randomized to either surgery alone (standard treatment, arm A) or to 6 cycles of neo-adjuvant oxaliplatin-based chemotherapy, followed by surgery (arm B). Patients must be &#x02265; 18 years of age with liver metastases of histologically confirmed primary colorectal carcinoma. Patients with extrahepatic metastases are excluded. Liver metastases must be deemed primarily resectable. Only patients with a CRS of 3&#x02013;5 are eligible. The primary study endpoint is OS. Secondary endpoints are progression free survival (PFS), quality of life, morbidity of resection, treatment response on neo-adjuvant chemotherapy, and whether CEA levels can predict treatment response.</p></sec><sec><title>Discussion</title><p>CHARISMA is a multicenter, randomized, phase III clinical trial that will provide an answer to the question if adding neo-adjuvant chemotherapy to surgery will improve OS in a well-defined high-risk patient group with colorectal liver metastases.</p></sec><sec><title>Trial registration</title><p>The CHARISMA is registered at European Union Clinical Trials Register (EudraCT), number: <ext-link ext-link-type="uri" xlink:href="http://www.trialregister.nl/trialreg/admin/rctsearch.asp?Term=4893">2013-004952-39</ext-link>, and in the &#x0201c;Netherlands national Trial Register (NTR), number: 4893.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Colorectal liver metastases</kwd><kwd>Neo-adjuvant chemotherapy</kwd><kwd>Surgical resection</kwd><kwd>Clinical risk score</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><sec id="Sec2"><title>Colorectal liver metastases: surgical treatment</title><p>Colorectal cancer (CRC) is one of the leading causes of cancer death. It is in the top 3 most commonly diagnosed cancers, with over 1.2 million new cases and over 600,000 deaths estimated to have occurred in 2008 worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. In approximately 20% of patients distant metastases are present at time of diagnosis [<xref ref-type="bibr" rid="CR2">2</xref>]. The liver is the most common metastatic site. Approximately 50% of patients with early-stage disease will eventually develop colorectal liver metastases (CRLM) [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>When metastases of CRC patients are restricted to the liver, possible curative treatment can be obtained by surgical resection. Complete surgical resection of CRLM improves 5-year survival rates to around 35-60% in selected patients [<xref ref-type="bibr" rid="CR5">5</xref>-<xref ref-type="bibr" rid="CR8">8</xref>]. However in only 10-20% of patients surgical resection of CRLM is feasible. Although surgery for CRLM provides the only potential for cure, cancer relapse is a common phenomenon, with a recurrence rate of up to 50% in the first 2 years after surgery [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec3"><title>Chemotherapy for colorectal liver metastases</title><p>Initially, systemic treatment with 5-fluoruracil based regimens was standard of care in CRLM, improving OS from 6 to 10&#x02013;12 months. The development of chemotherapeutic agents such as oxaliplatin and irinotecan has subsequently improved OS to a median of up to 24 months. Sequential treatment with all available cytotoxic agents, as well as the introduction of Epidermal Growth Factor receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF) binding monoclonal antibodies have further increased overall survival [<xref ref-type="bibr" rid="CR10">10</xref>-<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>The high relapse rate after curative resection of CRLM, and the efficacy of modern systemic treatment in the metastatic setting, have prompted investigators to perform numerous studies to evaluate the potential role of systemic chemotherapy combined with liver resection. The purpose of both adjuvant and neo-adjuvant chemotherapy is to treat microscopic disease that is not addressed by surgery. This microscopic disease may be promoting the high relapse rate that is observed after liver surgery [<xref ref-type="bibr" rid="CR9">9</xref>]. Notably, current literature suggests that timing of additional chemotherapy (adjuvant vs. neo-adjuvant) seems to have no influence on outcome [<xref ref-type="bibr" rid="CR14">14</xref>]. The role of perioperative chemotherapy in case of resectable CRLM was established in a randomized controlled trial [<xref ref-type="bibr" rid="CR15">15</xref>]. In the mature OS analysis of this trial there was no significant effect on OS after a median follow up of 7 years [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec4"><title>Stratification by clinical risk score</title><p>In the past, several clinical risk scores for the outcome of patients with CRLM have been published [<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR17">17</xref>-<xref ref-type="bibr" rid="CR25">25</xref>]. In 1999, Fong et al. described the most widely used CRS [<xref ref-type="bibr" rid="CR19">19</xref>]. This prognostic scoring system has been verified by independent investigators [<xref ref-type="bibr" rid="CR26">26</xref>]. Several authors have proposed the concept of stratification by CRS in relation to the effects of a multimodal treatment strategy on OS. These authors suggest that patients with a high risk score have a worse prognosis and might therefore benefit more from chemotherapy compared to patients with a low risk score [<xref ref-type="bibr" rid="CR27">27</xref>-<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>These findings have prompted others and ourselves to retrospectively evaluate data on patients who have undergone liver resection for CRLM in the last decade with and without chemotherapy, stratified by CRS according to the Fong-criteria [<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref>].</p><p>As described earlier, efforts to improve outcome of liver surgery by combining the resection with chemotherapy have failed to demonstrate definite OS benefit. This may partly be due to the fact that these studies often involve strict study protocol inclusion criteria. Consequently, patients with a high clinical risk score - which might benefit the most from chemotherapy - are often underrepresented in these studies. Since genuine survival benefit has not yet been demonstrated, could this low impact of chemotherapy on survival then be explained by the <italic>relatively</italic> low risk profile of the patients included in these trials?</p></sec><sec id="Sec5"><title>Study aim and hypothesis</title><p>The CHARISMA randomized clinical trial will evaluate the effect on OS of neo-adjuvant chemotherapy in patients with primary resectable CRLM and a CRS (Fong) of 3&#x02013;5, thereby bearing a poor prognosis. The primary aim of this study is to compare OS in patients with resectable liver metastases randomized for treatment with chemotherapy, consisting of capecitabine and oxaliplatin (XELOX), followed by surgery versus surgery alone.</p><p>We hypothesize that neo-adjuvant chemotherapy will provide an improvement in OS in this high-risk patient group. Secondary endpoints in this study will be progression free survival (PFS), quality of life as assessed by QLQ-30 and MFI questionnaires, response to chemotherapy, morbidity of surgery and resection rate, and whether carcinoembryonic antigen (CEA) can predict for treatment response, PFS, and OS.</p></sec></sec><sec id="Sec6"><title>Methods/Design</title><p>Patients with CRLM and a high CRS will be evaluated for inclusion by the local multidisciplinary team meeting. In this meeting, at least two surgeons with expertise in liver surgery should be present. In case of doubt, the imaging can be sent to a central expert panel. Patients are eligible for randomization if, in the opinion of a local expert panel, radical resection of the CRLM (R0-resection) is feasible.</p><p>Patients will be randomized 1:1 to either (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>):<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Study flowchart.</bold>
</p></caption><graphic xlink:href="12885_2015_1199_Fig1_HTML" id="d30e792"/></fig><list list-type="bullet"><list-item><p>
<bold>Arm A:Surgery of the liver metastases</bold>
</p></list-item><list-item><p>
<bold>Arm B:Neo-adjuvant oxaliplatin-based chemotherapy followed by surgery of the liver metastases</bold>
</p></list-item></list></p><sec id="Sec7"><title>Study population</title><sec id="Sec8"><title>Inclusion criteria</title><p>Age &#x02265; 18 years, ECOG performance status 0&#x02013;1. Histologically confirmed primary colorectal carcinoma. Radiological confirmed and primary resectable CRLM. CRS of 3&#x02013;5 (Fong). Adequate bone marrow, liver and renal functions.</p><p>Before any study related procedure will be pursued, written informed consent must be given according to ICH/GCP and national/local regulations.</p></sec><sec id="Sec9"><title>Exclusion criteria</title><p>Adjuvant chemotherapy for colorectal carcinoma given &#x0003c; 6 months prior to detection of the liver metastases. Prior non colorectal malignancies, except for basal or squamous cell carcinoma of the skin, or patients with carcinoma in situ of the cervix. Extrahepatic colorectal metastases. Locally advanced rectal cancer in situ requiring long-course pre-operative chemoradiotherapy. Major surgical procedures &#x0003c; 4 weeks prior to randomization. Pregnancy. History of psychiatric disability. Clinically significant cardiovascular disease. Uncontrolled hypertension. Lack of physical integrity of the upper gastro-intestinal tract, malabsorption syndrome, or inability to take oral medication. Known peripheral neuropathy. Organ allografts requiring immunosuppressive therapy. Serious, non-healing wound, ulcer, or bone fracture. Current or recent use of full-dose oral anticoagulants or thrombolytic agents for therapeutic purposes. Chronic treatment with corticosteroids. Serious intercurrent infections. Current or recent treatment with another investigational drug or participation in another investigational study. Psychological, familial, sociological or geographical conditions hampering compliance to the study protocol and follow-up schedule.</p></sec></sec><sec id="Sec10"><title>Assessment of operability</title><p>All patients have to be screened by their treating surgeon for fitness to undergo liver surgery. In case of doubt, formal anesthetic assessment is mandatory prior to randomization.</p></sec><sec id="Sec11"><title>Assessment of resectability</title><p>Prior to resection of the CRLM, an expert panel must review imaging of patients enrolled in this study in order to determine resectability. Resectability is defined as the possibility to achieve R0 resection. The liver remnant should comprise a portal vein, a hepatic artery, and a bile duct, one of the three main hepatic veins. The liver remnant should have sufficient liver function and 2 segments free of metastases at the time of resection.</p><p>If these prerequisites cannot be met, radiofrequency ablation (RFA) is allowed to obtain resectability. However, RFA may only be used in combination with liver resection if the number of lesions to be treated with RFA does not exceed 3 and the largest diameter of these lesions is less than 3 cm.</p></sec><sec id="Sec12"><title>Therapeutic regimen of patients Arm A</title><p>Patients should preferably be randomized within 2 weeks of the definitive diagnosis of CRLM. Patients allocated to Arm A should preferably have their surgery within 4 weeks after randomization and within 6 weeks after the last CT scan. Adjuvant chemotherapy after R0 resection is not allowed. Protocol therapy ends following the liver resection.</p></sec><sec id="Sec13"><title>Therapeutic regimen of patients Arm B</title><p>Patients in Arm B will receive 6 cycles of XELOX. Oxaliplatin will be administered in a 130 mg/m<sup>2</sup> dose, Capecitabine in a 1000 mg/m<sup>2</sup> dose. Patients should preferably be randomized within 2 weeks of the definitive diagnosis of CRLM. Patients allocated to Arm B should start neo-adjuvant chemotherapy preferably within 2 weeks after randomization and within 4 weeks after the last CT scan. Treatment evaluation will occur after the 3<sup>rd</sup> and 6<sup>th</sup> chemotherapy cycle. In the case of progressive disease (PD) after the 3<sup>rd</sup> cycle, a resectability check will take place. If patients remained resectable, they will be planned for surgery within 4&#x02013;6 weeks after completion of the 4<sup>th</sup> cycle. If patients are assessed to be irresectable, they will go off study protocol, but will be analyzed according to intention to treat principle.</p><p>After the last day of chemotherapy exposure, resection should take place at least 4 weeks, but at maximum 6 weeks later. Treatment evaluation can take place according to local hospital procedures, but should at least consist of a CT scan of the thorax/abdomen and CEA level. Adjuvant chemotherapy after R0 resection is not allowed. Protocol therapy ends following the liver resection.</p></sec><sec id="Sec14"><title>Endpoint</title><sec id="Sec15"><title>Primary endpoint</title><p>Primary endpoint of the study will be OS, calculated from the date of randomization to the date of death of the patient, from any cause. Patients still alive at the date of last contact will be censored.</p></sec><sec id="Sec16"><title>Secondary endpoints</title><p>PFS will be defined from the date of randomization to the first event defined as local/distant recurrence or progression or death from any cause.</p></sec></sec><sec id="Sec17"><title>Criteria of evaluation</title><p>Progressive or recurrent disease can be detected by imaging modalities (e.g. CT scan). A rise in serum tumor marker (e.g. CEA) is insufficient. In case of doubt, histological biopsy can provide definitive proof of progression/recurrence. Response to neo-adjuvant chemotherapy will be evaluated by CT scan using RECIST 1.1 criteria [<xref ref-type="bibr" rid="CR32">32</xref>]. To evaluate the well-being of patients the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QoL) will be used. The EORTC QLQ-C30 is generally used to assess QoL of cancer patients; additionally the Multifactorial Fatigue Index (MFI) will be used. Toxicity will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Surgical complications will be defined according to the standard classification of surgical complications [<xref ref-type="bibr" rid="CR33">33</xref>]. Postoperative mortality will be defined as any death during hospitalization or within 30 days from surgery. Complication and post-operative mortality rates will be securely monitored and documented.</p></sec><sec id="Sec18"><title>Statistical considerations</title><sec id="Sec19"><title>Sample size and accrual</title><p>On the basis of retrospective data, we expect the hazard ratio (HR) for arm B to be 0.60. For the detection of a HR of 0.60 for the chemotherapy arm and with an expected 5-year OS of 25% in arm A, with two-sided significance level &#x003b1; = 0.05 and power 1 - &#x003b2; = 0.8, 126 deaths have to be reported before the final analysis will take place. This number of events is expected to be reached after the recruitment of 224 patients with an average accrual rate of 56 patients per year, and an additional follow up of 2 years. A HR = 0.60 corresponds to an increase of 5-year OS of 43% in arm B.</p></sec></sec><sec id="Sec20"><title>Randomization</title><p>Eligible patients should be registered after written informed consent and before start of treatment (based on inclusion/exclusion criteria). Patients will be randomized for surgery versus neo-adjuvant chemotherapy followed by surgery in a 1:1 design. During randomization patients will be stratified by center, CRS score and status of primary tumor (still in situ vs. resected) with a minimization procedure, ensuring balance within each stratum and overall balance.</p></sec><sec id="Sec21"><title>Statistical analysis plan</title><p>The main analysis addressing the primary endpoint is planned after 126 events. No interim analysis is planned.</p></sec><sec id="Sec22"><title>Ethics</title><p>The study has ethical approval from the Erasmus MC medical-ethical committee. The study will be conducted in accordance with the ethical principles of the Declaration of Helsinki, the ICH-GCP Guidelines, the EU Clinical Trial Directive (2001/20/EG), and applicable regulatory requirements. The local investigator is responsible for the proper conduct of the study at the study site.</p></sec></sec><sec id="Sec23" sec-type="discussion"><title>Discussion</title><p>Currently, multimodal treatment is not incorporated in the standard of care for primary resectable colorectal liver metastases. To date, no definite evidence exists favoring administration of (neo) adjuvant chemotherapy in CRLM in addition to surgery. Considering the retrospective observations that pre-selection of patients by clinical prognostic characteristics may define a patient population expected to benefit from chemotherapy, CRS stratification provides the base for this randomized controlled trial.</p><p>Preceding studies of peri-operative chemotherapy combined with liver surgery often engaged strict study protocol inclusion criteria. Consequently, patients with a high CRS - which might benefit the most from chemotherapy - are often underrepresented in these studies. Possibly, this low impact of chemotherapy on survival could be explained by the <italic>relatively</italic> low risk profile of the patients included in these trials. Recently, two reports on patients with relatively low risk for recurrence have been published. Adam et al. performed an analysis of the LiverMetSurvey database on patients with solitary, metachronous, primarily resectable metastases. These patients have particularly favorable tumor biology and a low CRS. The authors concluded that these patients do not benefit from preoperative chemotherapy [<xref ref-type="bibr" rid="CR34">34</xref>]. A recent systematic review of the literature by Lehmann et al. concludes that routine use of neo-adjuvant chemotherapy for patients with clearly resectable lesions limited to the liver is not recommended due to a lack of benefit on survival [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p>As mentioned before, several authors have proposed the concept of stratification by CRS with regard to the effects of systemic therapy. Tomlinson et al. demonstrated on actual 10-year survivors of liver surgery for CRLM that patients with a low CRS had a cure rate of 21% and that patients with a high CRS had a cure rate of 10% [<xref ref-type="bibr" rid="CR27">27</xref>]. They suggest that this finding may be used to identify patients who might benefit from neo-adjuvant chemotherapy [<xref ref-type="bibr" rid="CR27">27</xref>]. In a large, non-randomized study by Parks et al., adjuvant therapy did seem to improve OS [<xref ref-type="bibr" rid="CR28">28</xref>]. In this study, patients with a high CRS had more benefit from adjuvant therapy than patients with a low CRS, again suggesting a role for CRS when considering chemotherapy.</p><p>These reports have stimulated others and our own unit to retrospectively evaluate data on patients that underwent liver resection for CRLM in the last decade with and without chemotherapy, stratified by CRS according to the Fong-criteria [<xref ref-type="bibr" rid="CR19">19</xref>]. Rahbari et al. have evaluated the role of adjuvant chemotherapy in a cohort of 316 patients, of whom 43% were high-risk according to the &#x0201c;Memorial Sloan-Kettering Cancer Center CRS&#x0201d; (CRS &#x0003e; 2). They found that adjuvant chemotherapy had a profound impact on OS in the high-risk population (HR = 0.40), whereas in low-risk patients HR = 0.90 [<xref ref-type="bibr" rid="CR31">31</xref>]. In a recent manuscript by Hirokawa et al. similar results are described with de use of adjuvant chemotherapy [<xref ref-type="bibr" rid="CR36">36</xref>]. In our population of patients that underwent resection for CRLM in Rotterdam (N = 365), we have focused on neo-adjuvant chemotherapy. In this study, a pronounced improvement in OS was found in high-risk patients receiving neo-adjuvant chemotherapy versus no chemotherapy (median 67 months vs. 33 months, HR = 0.55 [95% CI 0.35-0.84], p = 0.006). This difference was absent in the low-risk group (median 65 months vs. 56 months, HR = 0.89 [95% CI 0.57-1.40], p = 0.62) [<xref ref-type="bibr" rid="CR30">30</xref>]. Notably, these studies were retrospective and non-randomized. The sample size calculation of the present study is based on these retrospective data.</p><p>In a recent editorial by Jarnagin et al. it is suggested that future trials should strongly consider stratification by some scoring system [<xref ref-type="bibr" rid="CR29">29</xref>], given the results of the retrospective studies as mentioned above. Our study will evaluate patients with resectable CRLM without extra hepatic disease and a CRS of 3&#x02013;5 thereby bearing a poor prognosis. The primary aim of this study is to compare OS rates of patients with resectable liver metastases randomized for treatment with chemotherapy consisting of capecitabine and oxaliplatin (XELOX) followed by surgery, versus surgery alone. We hypothesize that adding neo-adjuvant chemotherapy to surgical resection of CRLM will provide an improvement in OS in patients with a high-risk profile. As secondary objectives we will study PFS, quality of life, treatment response on neoadjuvant chemotherapy, morbidity of surgery and resection rate, and whether CEA can predict for treatment response, PFS, and OS.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CEA</term><def><p>Carcinoembryonic antigen</p></def></def-item><def-item><term>CRC</term><def><p>Colorectal cancer</p></def></def-item><def-item><term>CRLM</term><def><p>Colorectal liver metastases</p></def></def-item><def-item><term>CRS</term><def><p>Clinical risk score</p></def></def-item><def-item><term>ECOG</term><def><p>Eastern cooperative oncology group</p></def></def-item><def-item><term>OS</term><def><p>Overall survival</p></def></def-item><def-item><term>PFS</term><def><p>Progression free survival</p></def></def-item><def-item><term>RCT</term><def><p>Randomized controlled trial</p></def></def-item><def-item><term>RFA</term><def><p>Radiofrequency ablation</p></def></def-item><def-item><term>XELOX</term><def><p>Chemotherapy consisting of capecitabine and oxaliplatin</p></def></def-item></def-list></glossary><fn-group><fn><p>Ninos Ayez and Eric P van der Stok contributed equally to this work.</p></fn><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>DG, the principal investigator on the CHARISMA trial, is extensively involved with the CHARISMA study concept and design. CV, head of department, sponsor, co-principal investigator, and DG are involved in supervising the study; critically revising the study protocol manuscript. NA, ES, co-investigators on the CHARISMA trial, are involved in drafting and critically revising the study protocol manuscript; provide administrative and technical support. NvdM, trial manager of the CHARISMA trial, was involved in the revision of the protocol. BvdH, trial statistician, was involved in the study design and protocol revision. JW, SR, RH, RR, GV, PT, CP, CD, RJ, HV, KJ, GH, JK, ML, EM, FS, are members of the writing committee. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The outline of this trial was developed at the EORTC course Methods in Clinical Cancer Research, Flims, Switzerland, June 2012. This study is funded by the Dutch Cancer Society.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name></person-group><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><year>2011</year><volume>61</volume><issue>2</issue><fpage>69</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.3322/caac.20107</pub-id><pub-id pub-id-type="pmid">21296855</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Pool</surname><given-names>AE</given-names></name><name><surname>Damhuis</surname><given-names>RA</given-names></name><name><surname>Ijzermans</surname><given-names>JN</given-names></name><name><surname>de Wilt</surname><given-names>JH</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Kranse</surname><given-names>R</given-names></name><etal/></person-group><article-title>Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series</article-title><source>Colorectal Dis</source><year>2010</year><volume>14</volume><issue>1</issue><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1318.2010.02539.x</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengmark</surname><given-names>S</given-names></name><name><surname>Hafstrom</surname><given-names>L</given-names></name></person-group><article-title>The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy</article-title><source>Cancer</source><year>1969</year><volume>23</volume><issue>1</issue><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(196901)23:1&#x0003c;198::AID-CNCR2820230126&#x0003e;3.0.CO;2-J</pub-id><pub-id pub-id-type="pmid">5763253</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Pool</surname><given-names>AE</given-names></name><name><surname>Lalmahomed</surname><given-names>ZS</given-names></name><name><surname>de Wilt</surname><given-names>JH</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Ijzermans</surname><given-names>JM</given-names></name><name><surname>Verhoef</surname><given-names>C</given-names></name></person-group><article-title>Local treatment for recurrent colorectal hepatic metastases after partial hepatectomy</article-title><source>J Gastrointest Surg</source><year>2009</year><volume>13</volume><issue>5</issue><fpage>890</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/s11605-008-0794-2</pub-id><pub-id pub-id-type="pmid">19132450</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dols</surname><given-names>LF</given-names></name><name><surname>Verhoef</surname><given-names>C</given-names></name><name><surname>Eskens</surname><given-names>FA</given-names></name><name><surname>Schouten</surname><given-names>O</given-names></name><name><surname>Nonner</surname><given-names>J</given-names></name><name><surname>Hop</surname><given-names>WC</given-names></name><etal/></person-group><article-title>[Improvement of 5 year survival rate after liver resection for colorectal metastases between 1984&#x02013;2006]</article-title><source>Ned Tijdschr Geneeskd</source><year>2009</year><volume>153</volume><issue>11</issue><fpage>490</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">19402322</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Primrose</surname><given-names>JN</given-names></name></person-group><article-title>Surgery for colorectal liver metastases</article-title><source>Br J Cancer</source><year>2010</year><volume>102</volume><issue>9</issue><fpage>1313</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605659</pub-id><pub-id pub-id-type="pmid">20424612</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>M</given-names></name><name><surname>Tekkis</surname><given-names>PP</given-names></name><name><surname>Welsh</surname><given-names>FK</given-names></name><name><surname>O&#x02019;Rourke</surname><given-names>T</given-names></name><name><surname>John</surname><given-names>TG</given-names></name></person-group><article-title>Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients</article-title><source>Ann Surg</source><year>2008</year><volume>247</volume><issue>1</issue><fpage>125</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e31815aa2c2</pub-id><pub-id pub-id-type="pmid">18156932</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Pool</surname><given-names>AE</given-names></name><name><surname>de Wilt</surname><given-names>JH</given-names></name><name><surname>Lalmahomed</surname><given-names>ZS</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Ijzermans</surname><given-names>JN</given-names></name><name><surname>Verhoef</surname><given-names>C</given-names></name></person-group><article-title>Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases</article-title><source>Br J Surg</source><year>2010</year><volume>97</volume><issue>3</issue><fpage>383</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1002/bjs.6947</pub-id><pub-id pub-id-type="pmid">20101594</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrelli</surname><given-names>NJ</given-names></name></person-group><article-title>Perioperative or adjuvant therapy for resectable colorectal hepatic metastases</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>30</issue><fpage>4862</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.5868</pub-id><pub-id pub-id-type="pmid">18794535</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurwitz</surname><given-names>H</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Novotny</surname><given-names>W</given-names></name><name><surname>Cartwright</surname><given-names>T</given-names></name><name><surname>Hainsworth</surname><given-names>J</given-names></name><name><surname>Heim</surname><given-names>W</given-names></name><etal/></person-group><article-title>Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><issue>23</issue><fpage>2335</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa032691</pub-id><pub-id pub-id-type="pmid">15175435</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><etal/></person-group><article-title>Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>12</issue><fpage>2013</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.9930</pub-id><pub-id pub-id-type="pmid">18421054</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Kohne</surname><given-names>CH</given-names></name><name><surname>Hitre</surname><given-names>E</given-names></name><name><surname>Zaluski</surname><given-names>J</given-names></name><name><surname>Chang Chien</surname><given-names>CR</given-names></name><name><surname>Makhson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><issue>14</issue><fpage>1408</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0805019</pub-id><pub-id pub-id-type="pmid">19339720</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Burkes</surname><given-names>R</given-names></name><name><surname>Barugel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>31</issue><fpage>4697</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.27.4860</pub-id><pub-id pub-id-type="pmid">20921465</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araujo</surname><given-names>R</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><name><surname>Allen</surname><given-names>P</given-names></name><name><surname>Blumgart</surname><given-names>L</given-names></name><name><surname>Dematteo</surname><given-names>R</given-names></name><name><surname>Fong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer</article-title><source>Ann Surg Oncol</source><year>2013</year><volume>20</volume><issue>13</issue><fpage>4312</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1245/s10434-013-3162-8</pub-id><pub-id pub-id-type="pmid">23897009</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Sorbye</surname><given-names>H</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Poston</surname><given-names>GJ</given-names></name><name><surname>Schlag</surname><given-names>PM</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><etal/></person-group><article-title>Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial</article-title><source>Lancet</source><year>2008</year><volume>371</volume><issue>9617</issue><fpage>1007</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60455-9</pub-id><pub-id pub-id-type="pmid">18358928</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Sorbye</surname><given-names>H</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Poston</surname><given-names>GJ</given-names></name><name><surname>Schlag</surname><given-names>PM</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><etal/></person-group><article-title>Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><issue>12</issue><fpage>1208</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70447-9</pub-id><pub-id pub-id-type="pmid">24120480</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minagawa</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>J</given-names></name><name><surname>Kosuge</surname><given-names>T</given-names></name><name><surname>Matsuyama</surname><given-names>Y</given-names></name><name><surname>Miyagawa</surname><given-names>S</given-names></name><name><surname>Makuuchi</surname><given-names>M</given-names></name></person-group><article-title>Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation</article-title><source>Arch Surg</source><year>2007</year><volume>142</volume><issue>3</issue><fpage>269</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1001/archsurg.142.3.269</pub-id><pub-id pub-id-type="pmid">17372052</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Guiguet</surname><given-names>M</given-names></name><name><surname>Vaillant</surname><given-names>JC</given-names></name><name><surname>Balladur</surname><given-names>P</given-names></name><name><surname>Boudjema</surname><given-names>K</given-names></name><name><surname>Bachellier</surname><given-names>P</given-names></name><etal/></person-group><article-title>Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie</article-title><source>Cancer</source><year>1996</year><volume>77</volume><issue>7</issue><fpage>1254</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19960401)77:7&#x0003c;1254::AID-CNCR5&#x0003e;3.0.CO;2-I</pub-id><pub-id pub-id-type="pmid">8608500</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>Y</given-names></name><name><surname>Fortner</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>RL</given-names></name><name><surname>Brennan</surname><given-names>MF</given-names></name><name><surname>Blumgart</surname><given-names>LH</given-names></name></person-group><article-title>Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases</article-title><source>Ann Surg</source><year>1999</year><volume>230</volume><issue>3</issue><fpage>309</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1097/00000658-199909000-00004</pub-id><pub-id pub-id-type="pmid">10493478</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwatsuki</surname><given-names>S</given-names></name><name><surname>Dvorchik</surname><given-names>I</given-names></name><name><surname>Madariaga</surname><given-names>JR</given-names></name><name><surname>Marsh</surname><given-names>JW</given-names></name><name><surname>Dodson</surname><given-names>F</given-names></name><name><surname>Bonham</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system</article-title><source>J Am Coll Surg</source><year>1999</year><volume>189</volume><issue>3</issue><fpage>291</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S1072-7515(99)00089-7</pub-id><pub-id pub-id-type="pmid">10472930</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagashima</surname><given-names>I</given-names></name><name><surname>Takada</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>K</given-names></name><name><surname>Adachi</surname><given-names>M</given-names></name><name><surname>Nagawa</surname><given-names>H</given-names></name><name><surname>Muto</surname><given-names>T</given-names></name><etal/></person-group><article-title>A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection</article-title><source>J Hepatobiliary Pancreat Surg</source><year>2004</year><volume>11</volume><issue>2</issue><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s00534-002-0778-7</pub-id><pub-id pub-id-type="pmid">15127268</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konopke</surname><given-names>R</given-names></name><name><surname>Kersting</surname><given-names>S</given-names></name><name><surname>Distler</surname><given-names>M</given-names></name><name><surname>Dietrich</surname><given-names>J</given-names></name><name><surname>Gastmeier</surname><given-names>J</given-names></name><name><surname>Heller</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases</article-title><source>Liver Int</source><year>2009</year><volume>29</volume><issue>1</issue><fpage>89</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2008.01845.x</pub-id><pub-id pub-id-type="pmid">18673436</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindl</surname><given-names>M</given-names></name><name><surname>Wigmore</surname><given-names>SJ</given-names></name><name><surname>Currie</surname><given-names>EJ</given-names></name><name><surname>Laengle</surname><given-names>F</given-names></name><name><surname>Garden</surname><given-names>OJ</given-names></name></person-group><article-title>Prognostic scoring in colorectal cancer liver metastases: development and validation</article-title><source>Arch Surg</source><year>2005</year><volume>140</volume><issue>2</issue><fpage>183</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/archsurg.140.2.183</pub-id><pub-id pub-id-type="pmid">15724001</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lise</surname><given-names>M</given-names></name><name><surname>Bacchetti</surname><given-names>S</given-names></name><name><surname>Da Pian</surname><given-names>P</given-names></name><name><surname>Nitti</surname><given-names>D</given-names></name><name><surname>Pilati</surname><given-names>P</given-names></name></person-group><article-title>Patterns of recurrence after resection of colorectal liver metastases: prediction by models of outcome analysis</article-title><source>World J Surg</source><year>2001</year><volume>25</volume><issue>5</issue><fpage>638</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/s002680020138</pub-id><pub-id pub-id-type="pmid">11369992</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>H</given-names></name><name><surname>Mochizuki</surname><given-names>H</given-names></name><name><surname>Hatsuse</surname><given-names>K</given-names></name><name><surname>Hase</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name></person-group><article-title>Indicators for treatment strategies of colorectal liver metastases</article-title><source>Ann Surg</source><year>2000</year><volume>231</volume><issue>1</issue><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1097/00000658-200001000-00009</pub-id><pub-id pub-id-type="pmid">10636103</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mala</surname><given-names>T</given-names></name><name><surname>Bohler</surname><given-names>G</given-names></name><name><surname>Mathisen</surname><given-names>O</given-names></name><name><surname>Bergan</surname><given-names>A</given-names></name><name><surname>Soreide</surname><given-names>O</given-names></name></person-group><article-title>Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome?</article-title><source>World J Surg</source><year>2002</year><volume>26</volume><issue>11</issue><fpage>1348</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1007/s00268-002-6231-x</pub-id><pub-id pub-id-type="pmid">12297926</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>JS</given-names></name><name><surname>Jarnagin</surname><given-names>WR</given-names></name><name><surname>DeMatteo</surname><given-names>RP</given-names></name><name><surname>Fong</surname><given-names>Y</given-names></name><name><surname>Kornprat</surname><given-names>P</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Actual 10-year survival after resection of colorectal liver metastases defines cure</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>29</issue><fpage>4575</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.11.0833</pub-id><pub-id pub-id-type="pmid">17925551</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><name><surname>Kemeny</surname><given-names>N</given-names></name><name><surname>Jarnagin</surname><given-names>W</given-names></name><name><surname>D&#x02019;Angelica</surname><given-names>M</given-names></name><name><surname>DeMatteo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents</article-title><source>J Am Coll Surg</source><year>2007</year><volume>204</volume><issue>5</issue><fpage>753</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2006.12.036</pub-id><pub-id pub-id-type="pmid">17481478</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarnagin</surname><given-names>WR</given-names></name><name><surname>D&#x02019;Angelica</surname><given-names>M</given-names></name></person-group><article-title>Systemic therapy for patients with resectable hepatic colorectal metastases: improving patient selection</article-title><source>Ann Surg Oncol</source><year>2014</year><volume>21</volume><issue>1</issue><fpage>11</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1245/s10434-013-3312-z</pub-id><pub-id pub-id-type="pmid">24121882</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ayez</surname><given-names>N</given-names></name><name><surname>Gr&#x000fc;nhagen</surname><given-names>DJ</given-names></name><name><surname>de Jonge</surname><given-names>J</given-names></name><name><surname>Ijzermans</surname><given-names>J</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Verhoef</surname><given-names>C</given-names></name></person-group><source>The role of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases</source><year>2011</year><publisher-loc>Orlando, Fl, USA</publisher-loc><publisher-name>SSO (abstr 87)</publisher-name></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahbari</surname><given-names>NN</given-names></name><name><surname>Reissfelder</surname><given-names>C</given-names></name><name><surname>Schulze-Bergkamen</surname><given-names>H</given-names></name><name><surname>Jager</surname><given-names>D</given-names></name><name><surname>Buchler</surname><given-names>MW</given-names></name><name><surname>Weitz</surname><given-names>J</given-names></name><etal/></person-group><article-title>Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy</article-title><source>BMC Cancer</source><year>2014</year><volume>14</volume><fpage>174</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-14-174</pub-id><pub-id pub-id-type="pmid">24612620</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Bogaerts</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>LH</given-names></name><name><surname>Sargent</surname><given-names>D</given-names></name><name><surname>Ford</surname><given-names>R</given-names></name><etal/></person-group><article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title><source>Eur J Cancer</source><year>2009</year><volume>45</volume><issue>2</issue><fpage>228</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><pub-id pub-id-type="pmid">19097774</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dindo</surname><given-names>D</given-names></name><name><surname>Demartines</surname><given-names>N</given-names></name><name><surname>Clavien</surname><given-names>PA</given-names></name></person-group><article-title>Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey</article-title><source>Ann Surg</source><year>2004</year><volume>240</volume><issue>2</issue><fpage>205</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000133083.54934.ae</pub-id><pub-id pub-id-type="pmid">15273542</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Bhangui</surname><given-names>P</given-names></name><name><surname>Poston</surname><given-names>G</given-names></name><name><surname>Mirza</surname><given-names>D</given-names></name><name><surname>Nuzzo</surname><given-names>G</given-names></name><name><surname>Barroso</surname><given-names>E</given-names></name><etal/></person-group><article-title>Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?</article-title><source>Ann Surg</source><year>2010</year><volume>252</volume><issue>5</issue><fpage>774</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e3181fcf3e3</pub-id><pub-id pub-id-type="pmid">21037433</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>K</given-names></name><name><surname>Rickenbacher</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>A</given-names></name><name><surname>Pestalozzi</surname><given-names>BC</given-names></name><name><surname>Clavien</surname><given-names>PA</given-names></name></person-group><article-title>Chemotherapy before liver resection of colorectal metastases: friend or foe?</article-title><source>Ann Surg</source><year>2012</year><volume>255</volume><issue>2</issue><fpage>237</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e3182356236</pub-id><pub-id pub-id-type="pmid">22041509</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirokawa</surname><given-names>F</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>Y</given-names></name><name><surname>Asakuma</surname><given-names>M</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Komeda</surname><given-names>K</given-names></name><etal/></person-group><article-title>Reconsideration of the indications for adjuvant chemotherapy for liver metastases from colorectal cancer after initial hepatectomy</article-title><source>Ann Surg Oncol</source><year>2014</year><volume>21</volume><issue>1</issue><fpage>139</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1245/s10434-013-3310-1</pub-id><pub-id pub-id-type="pmid">24121880</pub-id></element-citation></ref></ref-list></back></article>